Charles River Laboratories is a diagnostics & research business based in the US. Charles River Laboratories shares (CRL) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $118.46 – an increase of 3.31% over the previous week. Charles River Laboratories employs 18,700 staff and has a trailing 12-month revenue of around $4 billion.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $118.46 |
|---|---|
| 52-week range | $91.86 - $254.15 |
| 50-day moving average | $147.78 |
| 200-day moving average | $182.66 |
| Wall St. target price | $155.28 |
| PE ratio | 605.6842 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.19 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $118.46 from 2025-05-02
| 1 week (2025-04-25) | 3.31% |
|---|---|
| 1 month (2025-04-04) | -13.47% |
| 3 months (2025-02-04) | -27.38% |
| 6 months (2024-11-04) | -35.08% |
| 1 year (2024-05-03) | -49.26% |
|---|---|
| 2 years (2023-05-03) | -38.13% |
| 3 years (2022-05-03) | 251.19 |
| 5 years (2020-05-04) | 138.35 |
Valuing Charles River Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Charles River Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Charles River Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 606x. In other words, Charles River Laboratories shares trade at around 606x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Charles River Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.8038. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Charles River Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Charles River Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $898.2 million.
The EBITDA is a measure of a Charles River Laboratories's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4 billion |
|---|---|
| Operating margin TTM | 7.79% |
| Gross profit TTM | $1.4 billion |
| Return on assets TTM | 4.34% |
| Return on equity TTM | 0.71% |
| Profit margin | 0.55% |
| Book value | $67.69 |
| Market Capitalization | $5.7 billion |
TTM: trailing 12 months
We're not expecting Charles River Laboratories to pay a dividend over the next 12 months.
Over the last 12 months, Charles River Laboratories's shares have ranged in value from as little as $91.8609 up to $254.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Charles River Laboratories's is 1.45. This would suggest that Charles River Laboratories's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.